The selection of cases for randomised trials: a registry survey of concurrent trial and non-trial patients. The British Stomach Cancer Group. by Ward, L. C. et al.
Br. J. Cancer (1992), 66, 943 950 © Macmillan Press
The selection of cases for randomised trials: a registry survey of
concurrent trial and non-trial patients
L.C. Ward', J.W.L. Fielding2, J.A. Dunn', K.A. Kelly' for the British Stomach Cancer Group*
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Summary A randomised trial of adjuvant chemotherapy vs placebo in operable stomach cancer recruited 249
patients from the West Midlands Region between 1976-1980. A Cancer Registry survey identified a further
1261 suitable concurrent cases. Trial patients were compared with the 960 non-trial cases from participating
Districts. Only 493 (51%) non-trial cases passed all of the prospective trial selection criteria for entry. Stage
and fitness caused the majority of exclusions and were also highly prognostic.
A univariate analysis comparing eligible patients with the trial showed the two groups to be balanced for the
significant independent prognostic factors of the trial. However, differences in patient age and the surgery
performed indicate that recruitment may have been influenced by unknown selection factors. This survey
highlights the difficulty of retrospective selection and confirms the need for randomised controls. Data
available from specialist Registries may be used to help develop new protocols and to verify and extend trial
results.
The heterogeneity present in any population of cancer
patients underlies the need for carefully controlled and con-
ducted comparative studies. The prospective randomised con-
trolled trial (RCT) is the accepted method for the evaluation
of therapy. Despite this, the proportion of all newly diag-
nosed cancer patients entered into RCT's has improved little
over the past 10 years and is still less than 3% (Friedman &
Cain, 1990; Tate et al., 1979). Accrual to the available pro-
tocols is often poor and ways of improving recruitment are
being sought urgently. The extent of selection for RCT's has
led to concern that their findings may not be generally
applicable within the population and suggestions that studies
with high exclusion rates should attempt to document all
non-randomised patients (Elwood, 1982; Toronto Leukemia
Study Group, 1986). Much interest has focused on the diffi-
culty of obtaining informed consent and the need to
encourage wider clinical participation. Trial eligibility criteria
also have a direct influence on recruitment but their impor-
tance in defining the patients for study is often overlooked
(Begg & Engstrom, 1987).
The development of large, detailed medical databases has
re-opened the debate on the validity of possible alternatives
to the RCT. Clinicians now have vastly improved access to
patient information which may be used to help plan and
evaluate treatment policies (Califf et al., 1986). It is becoming
easier to obtain non-randomised or historical groups for
comparison that are matched for the main patient charac-
teristics and known prognostic factors. Differences in out-
come may then be attributed to the effect of therapy. This
approach largely circumvents the problem of obtaining con-
sent for randomisation and maximises the use of available
subjects (Gehan & Freireich, 1974). Despite these attractions,
data bases suffer the same or greater methodological difficul-
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ties as other non-randomised designs and must be approach-
ed with equal caution (Byar, 1980; 1988; Mantel, 1983). They
are only acceptable in the rare situations where a randomised
trial is not practical. Although new technical and statistical
approaches are being studied, it seems unlikely that alterna-
tive methods will approach the precision offered by the RCT
(McDonald & Hui, 1991).
There is a need for more empirical studies comparing non-
randomised and randomised outcomes. A potentially useful
approach advocated by the Coronary Artery Surgery Study
group, is to extend RCT's by prospective registration and
follow-up of all cases seen (CASS Principle Investigators and
Their Associates, 1984; Davis, 1988). This cohort method
may prove a valuable compromise in situations where a high
proportion of potential subjects are ineligible for entry or
refuse randomisation. However, comprehensive screening
adds to the cost and complexity of running a clinical trial
and few cancer trial cohorts have been reported. Cancer
Registries are an existing source of descriptive information
on patients. Population based incidence and mortality rates
can be used to help monitor the overall progress against
cancer, while the level of participation in clinical trials is
considered a good indicator of the delivery of optimum care
(Extramural Committee to Assess Measures of Progress
Against Cancer, 1990). In the United Kingdom, specialist,
incidence based Registries offer the opportunity to measure
the true impact of large Phase III trials in the community.
We describe a collaborative study carried out by the
British Stomach Cancer Group (BSCG) and the West Mid-
lands Cancer Registry (the Registry). The first BSCG trial
(BSCG-1) represented an attempt to intervene in the manage-
ment of operable stomach cancer within the West Midlands
Region. Subjects were recruited with the intention to give
adjuvant combination chemotherapy for a period of 2 years
while the standard therapy outside the trial remained surgery
alone. The target population of patients considered suitable
for adjuvant chemotherapy was broadly defined as all cases
of resected gastric carcinoma aged between 15 and 74. A
Cancer Registry survey has been performed to document all
potential trial subjects seen during the period of recruitment.
The resulting cohort of trial and non-trial patients has been
studied. Entry to the trial was further restricted to cases
which passed a number of exclusion criteria. These detailed
selection rules were applied retrospectively to the non-trial
cases in order to identify and exclude ineligible patients from
the survey. Their effect on the numbers, survival and com-
position of the non-trial group is described.
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Subjects and methods
BSCG-1 was a prospective randomised trial of adjuvant
chemotherapy in operable gastric cancer which recruited 411
patients from England during 1976 to 1980. The trial proto-
col has been described (Fielding et al., 1983). Patients with
histologically proven, resected primary carcinoma of the
stomach aged between 15-74 were suitable for referral to the
trial. Following operation to remove the primary tumour,
patients were randomised to a 2 year maintenance course of
either 5-Fluorouracil plus mitomycin-C given every 3 weeks
or placebo. With follow-up of 5.5 years, the adjuvant therapy
has failed to provide any survival advantage (Allum et al.,
1989a). The National trial recruited 249 (61%) of patients
from the West Midlands Region. These are representative of
the overall trial, entry having been stratified by centre, and
show no difference in survival between treatment and placebo
(X2 = 0.95, P = 0.33).
Other patients meeting the above criteria and treated dur-
ing the period of recruitment to BSCG-1 were identified
through the Registry. The detection rate for all new tumours
is estimated to be 98% (Waterhouse et al., 1976). In addition
to basic incidence data, the Registry routinely records exten-
sive information on patient characteristics, the extent of
disease at presentation and the method of clinical manage-
ment (Fielding et al., 1989). However, all the data required to
stage patients and assess eligibility for the trial could not be
extracted directly from the Registry data base. We also
wished to compare the accuracy and completeness of data
collected for cancer registration purposes with prospectively
coded trial data. The Registry notes of each case were there-
fore reviewed by the BSCG data manager and clinical
research fellow to complete the standard trial entry form.
Attention was focused on determining the stage of disease
following operation using the classification used by the
BSCG (Fielding et al., 1983). Where the operation could not
be categorised as palliative or curative it was not possible to
stage the patient. Pathologists were contacted to provide the
data required to stage curatively resected cases.
Assessment ofeligibility
The process of confirming eligibility for the trial relied upon
checking a series of exclusion criteria prior to randomisation.
The eligibility of non-trial patients was tested by applying
these exclusion criteria retrospectively (Table I). Although
failure to pass any criterion would cause exclusion, their
individual effect in controlling patient numbers and prognosis
might vary. In a retrospective study, it may be possible to
identify the more important critera which need to be very
clearly defined to produce a well matched group for com-
parison. Selection was weighted in favour of the more objec-
tive retrospective tests by ranking them in a general order of
reliability. Criteria were then applied successively in order of
rank to both groups. Patients remaining eligible for study
have been compared at each step.
All patients in the survey were considered to have been
potentially eligible for randomisation to the trial providing
they lived in the Region, had histologically confirmed adeno-
carcinoma and no previous history of malignancy, chemo-
therapy or radiotherapy. Patients with stage 1 or stage 4
(unresectable) disease were excluded as were those with
significant post operative complications or other serious
disease sufficient to prevent chemotherapy starting within 12
weeks of operation. Those known to have had elective
adjuvant chemotherapy were considered to have effectively
refused consent. On review a number of cases registered as
stomach had clearly been diagnosed and treated for an
esophageal or unknown primary. These were excluded since
the original intention was not to treat a stomach cancer. Any
valid reason not to randomise was recorded at review. If any
criterion could not be assessed the patient was considered
ineligible.
Analysis
Duration of survival was the primary end point. Survival
time was defined as time from operation to death. Follow up
through Cancer Registration was censored on 18th August
1987, with a minimum duration of follow up of 6.8 years.
Survival curves were drawn for the univariate analysis of
survival using the method of Kaplan and Meier (1958).
Log-rank tests have been used for the statistical comparison
between the curves (Peto et al., 1977).
Differences in patient characteristics between the groups
have been estimated by the Pearson Chi square, Yates cor-
rected Chi square, or Chi square for trend, where appropriate
in ordered categorical data. The distribution of non-normal/
skewed data (age and duration of symptoms) were compared
using the Mann-Whitney rank sum test. The statistical
analyses were performed using the BMDP statistical package
(Dixon et al., 1988), at the Cancer Research Campaign Trials
Unit in Birmingham.
Results
A total of 1,510 cases were identified as suitable for referral
to the trial and entered to the survey. Districts which did not
Table I Exclusion criteria applied to select eligible non-trial and trial patients
Excludedpatients
1 Able to attend
2 Histology
3 History
4 Stage
5 Fitness (to start chemotherapy
within 12 weeks of surgery)
6 Informed consent
7 Delayed referral
8 Diagnosis
9 Not evaluable
(i) Patient living outside Region at time of treatment.
(i) Not pathologically confirmed adenocarcinoma of stomach.
(ii) Carcinoma in situ.
(i) Previous tumour registration for frank malignant condition.
(not basal cell carcinoma of skin, ca in situ of cervix, pre-malignant conditions)
(ii) Previous treatment with chemotherapy or radiotherapy.
(i) Stage 1: Curative resection, Histologically node, serosa and resection lines negative (N-S-L).
(ii) Stage 4 (Not operable).
(i) Major complications following surgery.
(ii) Impaired renal function following surgery.
(iii) Unrelieved obstruction following surgery.
(iv) Post operative deaths within 28 days of data of operation.
(v) Other significant intercurrent disease.
(i) If referred to trial: Refused randomisation or refusal following entry on study.
(ii) If not referred: Other adjuvant therapy given as elective treatment.
(i) Referred to trial more than 12 weeks after operation.
(i) Diagnosed at time ofinitial treatment as an unknown primary site.
(ii) Treated for an esophageal tumour.
(iii) Other than cancer arising in stomach.
(i) Missing pathological type or stage or resectability not confirmed.
(ii) Notes unavailable or inadequate for review.
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take part in the trial were responsible for 301 (20%) cases
which will not be discussed further. Thirteen of the 22 Dis-
trict Hospital Authorities in the Region did participate and
treated 1,209 (80%) cases. Of these 960 (79%) failed to enter
the trial and provide the non-trial group for comparison with
the 249 (21%) randomised patients.
Exclusions due to eligibility criteria
There were 32 (13%) withdrawals from the trial as a result of
protocol violations (four cases of previous malignancy, 20
pre-treatment deaths and eight who withdrew consent). Every
criterion caused cases to be lost from the non-trial group
(Table II). The greatest losses were due to staging which
excluded 93 (9%) cases and by the criterion of fitness which
was failed by 212 (22%) cases. The majority of 'unfit' cases
were deaths within 28 days of operation (129/212), with the
remaining 83 cases having evidence of non-fatal complica-
tions or other serious intercurrent disease. The criterion of
consent excluded four cases who refused chemotherapy and
36 cases who were given adjuvant treatment outside the trial.
Half of the referable cases in the non-trial group failed to
pass one or more of the exclusion criteria and thus were not
eligible for randomisation. The remaining 493 (51%) eligible
non-trial cases formed the best possible group for com-
parison with the 217 evaluable trial cases. A third (31%) of
all eligible patients seen by participating hospitals had been
randomised into the trial.
Effect ofeligibility criteria on survival
The influence of each exclusion criterion on survival of the
non-trial and trial patients is shown in Table III. The steps
correspond to those in Table II, with step 0 showing survival
for both groups for all patients eligible for the survey. Each
successive step shows the survival after eliminating patients
who did not meet the eligibility criterion for that step.
At entry in step 0, the trial showed a moderate survival
advantage (X = 3.76, P= 0.05) over all the non-trial patients
entered in the survey. The benefit was confined to the first 2
years (Figure 1). At 12 months 51% of the trial were alive
and 41% of the non-trial patients. However, by 2 years the
relative survival rates in trial and non-trial were 26% and
27% respectively. Exclusion of early stage I cases (Figure 2)
worsened the prognosis of the non-trial group and gave a
highly significant survival advantage to trial patients (2=
14.68, P = 0.0001). The criterion of fitness also had a direct
effect on survival by excluding all deaths in the first 28 days.
This negated the difference in survival between the groups
(7 =2.13, P=0.14).
When all criteria were applied (Figure 3) the final groups
for comparison showed very similar survival (X2= 1.41, P =
0.24). This concurs with the trial findings for placebo vs
treatment. There is thus no evidence from these data to
indicate that the trial cases behaved differently to comparable
patients treated in participating centres during the same
period.
Table II Stepwise application of criteria to non-trial group: losses due to exclusions and
proportion ofeligible cases randomised
Criterion
Eligible for survey
Able to attend
Histology
History
Stage
Fitness
Consent
Delayed referral
Diagnosis
Not evaluable
Total eligible
Fail
(n)
5
13
28
93
212
40
12
40
24
Non-trial cases
(n = 960)
Pass
(n)
960
955
942
914
821
609
569
557
517
493
493
Remaining
eligible (%)
100
99
98
95
86
63
59
58
54
51
All cases
(n = 1209)
Eligible Randomised to
(n) trial (%)
1209 20.6
1204 20.7
1191 20.9
1159 21.1
1066 23.0
834 27.0
786 27.6
774 28.0
734 29.6
710 30.6
710
Table III Stepwise application of eligibility criteria: effect on survival in non-trial and trial groups
Alive Median
at start survival OIE
Step Criterion applied (n) months (95% CI) deaths x2 p
0 Eligible for survey Non-trial 960 9 (8,10) 1.03 3.76 0.05
Trial 249 12 (11,14) 0.89
1 Able to attend Non-trial 955 9 (8,10) 1.03 3.98 0.05
Trial 249 12 (11,14) 0.89
2 Histology Non-trial 942 9 (9,10) 1.04 4.35 0.04
Trial 249 12 (11,14) 0.89
3 History Non-trial 914 9 (8,10) 1.04 4.06 0.04
Trial 245 12 (11,14) 0.89
4 Stage Non-trial 821 8 (7,9) 1.08 14.68 0.0001
Trial 245 12 (11,14) 0.80
5 Fitness Non-trial 609 11 (10,13) 1.03 2.13 0.14
Trial 225 13 (12,16) 0.93
6 Consent Non-trial 569 11 (10,13) 1.03 1.42 0.23
Trial 217 13 (12,16) 0.93
7 Delayed referral Non-trial 557 11 (10,13) 1.03 1.58 0.21
Trial 217 13 (12,16) 0.93
8 Diagnosis Non-trial 517 11 (10,13) 1.03 1.68 0.20
Trial 217 13 (12,16) 0.93
9 Not evaluable Non-trial 493 11 (10,13) 1.03 1.41 0.24
Trial 217 13 (12,16) 0.93
Step
0
2
3
4
5
6
7
8
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Characteristics ofeligible patients
The characteristics of patients in the non-trial and trial
groups were compared in the 710 cases which passed all tests
of eligibility (Table IV). Any clinical bias in the selection of
cases for randomization might be detectable at this point and
it is interesting that more younger patients were included in
the trial. This difference was significant using both the Mann-
Whitney test (t = 8.77, P = 0.003) and the chi square test
for linear trend (X2t,nd = 10.54, P = 0.001), although the
median ages were comparable (non-trial 64 years, range
27-74, trial 63 years, range 33-74). Longer history has been
reported to be associated with younger age and improved
prognosis (Brookes et al., 1965; Fielding 1989b), and entry to
the trial was stratified by symptoms of greater than or less
than 6 months. We found that more trial patients reported a
longer symptomatic history (X2 = 8.77, P = 0.003). However,
these data were missing in 119/493 (24%) of the non-trial
patients and this finding may be an artefact of less detailed
reporting in the non-trial group.
Stage of disease following surgery was equally distributed
and there was no evidence that this had influenced selection
of cases for adjuvant treatment. Examination of the findings
at operation shows that the groups were well matched with
respect to surgical stage as shown by the surgeon's ability to
attempt a curative operation and the extent of residual
primary and metastatic spread. Proximal tumours have been
associated with poorer prognosis (Brookes et al., 1965; Curtis
et al., 1985). The non-trial group contained significantly more
tumours originating in the upper part of the stomach and
fewer in the lower third (X2tnds = 5.97, P = 0.02). Surgical
procedure was strongly influenced by the site of tumour and
overall 89% (113/127) of the partial proximal resections were
performed on non-trial patients (X2 = 32.08, P = 0.0001).
Primary tumours of non-trial patients were more frequently
reported to have spread to involve more than one zone
within the stomach (x2 = 9.97, P = 0.002). Differences in sur-
gical referral patterns may account for these imbalances.
The pathological findings confirm that the groups were
fairly well matched with no large imbalances in involvement
of serosa, lymph nodes or resection lines. The combined
pathological stage showed slightly more stage 2 cases (S +,
N -, L -) in the non-trial group (X2 = 3.70, P = 0.05) which
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Figure 3 Survival of trial vs non-trial: All ineligible cases excluded.
also contained fewer tumours over
P= 0.001).
5 cm (X2 = 10.44,
Missing data
Prospective collection of data ensured that the trial data were
virtually complete in randomised cases. The non-trial group
had more missing data with duration of symptoms (24%)
and resection line involvement (21%) being very badly
reported. Data which were not prospectively recorded by the
trial, such as differentiation, tumour size and histological
type were equally documented in both groups.
Discussion
This survey has identified the target population of a prospec-
tive, randomised regional trial. The study was not confined
to specialist centres or reliant on clinicians to flag cases. A
formal review of all Registry case notes was performed to
confirm the eligibility and trial entry data of the concurrent,
non-randomised patients. Since the trial selection criteria did
not require additional diagnostic or laboratory tests they
could be studied retrospectively. Their importance in restric-
ting patient numbers has been demonstrated with 49% of the
non-trial cases proving ineligible for randomisation. Exclud-
ing these produced a better matched group for comparison
and showed that 31% of eligible patients were recruited into
the trial. A retrospective, incidence based survey would be
expected to overestimate the number of eligible cases present-
ing to trial clincs. Despite this, the levels of patient eligibility
and accrual reflect the experience reported by other groups.
The VA cooperative study found that 57% of 2,698 patients
screened for entry into active cancer protocols were ineligible.
Of the 1,144 eligible cases, 38% were randomised, the
clinician refused in 42% and the remaining 20% of patients
refused (Martin et al., 1981). The Rochester Cancer Registry
performed a case control study of entry into four ECOG
lung protocols during the early 1970's (McCusker et al.,
1982). On detailed review of the medical records, 189/363
(52%) cases were found to be ineligible for any protocol. Of
the 174 eligible patients, 65 (37%) were randomised. A study
of recruitment performed in ECOG centres found that only
1202 (34%) of the 3534 patients sampled had a protocol
available. Of these, 54% were randomised, the clinician
refused in 24%, the patient refused in 9% and the remaining
13% of cases were technically unsuitable (Begg et al., 1983).
The St Louis radiotherapy centre screened all 1103 patients
referred for admission during 1979. This survey showed that
the majority (64%) could not be considered for any of the 64
protocols open. Of 400 patients with a protocol available,
34% were technically ineligible. Nearly half (48%) of the 263
cases which met all entry criteria were entered onto a pro-
tocol. The referring clinicians effectively prevented 33% from
being randomised to treatment, while the radiotherapists at
the centre refused to enter 11%. Patient preference for a
given treatment was exercised in only 8% (Lee & Breaux,
1983).
The CCOP physician's patient log showed that 48% of
16,996 patients screened during 1984-1985 were ineligible for
any open National Cancer Institute protocol. One third of all
eligible patients were entered onto studies, with 51% of
exclusions due to the clinicians' refusal and 32% due to the
patients refusing (Hunter et al., 1987). A survey of trials in
the National Institute of Health Register for 1979 found that
recruitment of eligible cases averaged 56% in 16 trials which
kept full records (Charlson & Horowitz, 1984). In the Coron-
ary Artery Surgery Study of surgery vs medical management
37% of all eligible cases were randomised (CASS Principle
Investigators and Their Associates, 1984). The present
EORTC trial of observaton vs radiotherapy for DCIS of the
breast has reported that the majority (60%) of cases are
ineligible for study, with only 4% of exclusions being caused
by patient refusal (Fentiman et al., 1991). In contrast, the
current CRC trial of tamoxifen and surgery vs tamoxifen
alone in elderly women with breast cancer has reported a
refusal rate of 57% (Bates et al., 1991). In our study, it was
encouraging to find that patient refusal accounted for 5% of
all known exclusions and that only 3% of cases in the
Region were given unproven adjuvant chemotherapy outside
the protocol.
Clinical preference when determining the choice of treat-
ment of individual patients has been repeatedly identified as
one of the main factors limiting recruitment. In consequence,
many potential volunteers are not offered randomisation into
suitable trials. It is argued that such patients should be
informed of the existence of alternative therapeutic options
(Baum et al., 1989; Chalmers, 1990). A less controversial
proposal is to adopt less restrictive entry criteria and thus
increase the numbers eligible for study (Yusef et al., 1990).
The possibilities for improving accrual are illustrated by this
BSCG trial in which 20% of possible subjects lived outside
the catchment area covered by the participating hospitals,
and an arbitrary 74 year upper age limit excluded 31% of all
new cases from consideration (Fielding, 1989a).
This survey illustrates the situation where adjuvant treat-
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Table IV Comparison of the characteristics ofeligible non-trial and trial groups
Non-trial Trial
(n = 493) (n = 217) Odds ratioa
no. % no. % OR 95% CI X2 DF P
Characteristics at presentadon
Age groups
15-55
56-65
66-74
Sex
Male
Female
Duration ofsymptoms
<6 months
>6 months
(Not known)
Stage ofdisease
2
3a
3bc
Operation details
Intent ofsurgery
Curative
Palliative
(not known)
Macroscopic clearance
Complete excision
Tumour left
(Not known)
Liver metastases
Nil
Present
(Not known)
Peritoneal metastases
Nil
Present
(Not known)
Site of tumour
Upper
Body
Lower
(Other/esophagus)
(Not known)
No. ofsites involved
1
2 or more
(Not known)
Type ofgastrectomy
Total
Proximal
Distal
(Unspecified partial)
(Not known)
Pathological findings
Serosal involvement
Negative
Positive
(Not known)
Lymph node involvement
Negative
Positive
(Not known)
Resection line involvement
Clear
Involved
(Not known)
Pathological stage
Stage 2 (S + N - L-)
Stage 3a (N + or L +)
(Stage I (S-N -L-))
(Not known)
Differentiation
Poor
Well
(Not known)
Size of tumour (cm)
0-5
>5
(Not known)
92 19
188 38
213 43
66 30
76 35 0.56 (0.37,0.85)
75 35 0.49 (0.33,0.74)
338 69 152 70
155 31 65 30 0.93 (0.66,1.32)
202 69 89 31
172 57 128 43 1.69 (1.20,2.37)
(119) (24)
88 18 33 15
261 53 127 59 1.30 (0.83,2,04)
144 29 57 26 1.06 (0.64,1.75)
344 72 152 74
137 28 54 26 0.89 (0.62,1.29)
(12) (2) (11) (5)
360 80 171 79
90 20 45 21 1.05 (0.70,1.57)
(43) (9) (1) (1)
438 94 207 95
30 6 10 5 0.71 (0.34,1.47)
(25) (5)
443 94 206 95
27 6 10 5 0.80 (0.38,1.68)
(23) (5) (1) (1)
94 24 33 17
120 31 58 29 1.38 (0.83,2.28)
175 45 108 54 1.76 (1.11,2.79)
(84) (17) (18) (8)
(20) (4)
337 71 179 82
136 29 38 18 0.53 (0.35,0.79)
(20) (4)
95 21 58 27
113 25 14 6 0.20 (0.11,0.39)
250 54 145 67 0.95 (0.65,1.40)
(32) (7)
(3) (1)
28 6 19 9
444 94 198 91 0.66 (0.36,1.20)
(21) (4)
135 28 46 21
342 72 169 79 1.45 (0.99,2.12)
(16) (3) (2) (1)
260 66 147 74
132 34 52 26 0.70 (0.48,1.02)
(101) (21) (18) (8)
110 23 35 16
375 77 180 84 1.51 (0.99,2.30)
(7) (1.0) (2) (1)
(1) (0.2)
248 61 127 69
160 39 58 31 0.71 (0.49,1.02)
(85) (17) (32) (15)
209 59 59 42
148 41 80 58 1.91 (1.29,2.85)
(136) (28) (78) (36)
105.b 1 0.001
0.16 1 0.69
8.77 0.003
1 0.96
0.27 1 0.61
0.06
0.88
0.36
1 0.80
1 0.35
1 0.55
5.97b 1 0.02
9.97 1 0.002
32.08 2 0.0001
1.90
3.70
3.16
3.70
3.39
10.44
1 0.17
1 0.06
1 0.08
1 0.05
1 0.07
1 0.001
Notes: ( )Bracketsindicatewhichcategorieshavebeenexcludedfromcomparative statistics;aOddsratiosarecalculatedfor
eachfactorusingthe 1stgroupasbaseline;e.g. forage 15-55iscomparedagainst56-65and 15-55compared against66-74.
bChi squared test for linear trend.
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ment is given only to trial patients. Controls receiving the
standard treatment were identified from a database. We were
interested to look at the feasibility of obtaining a reliable
control group for restrospective survival comparison from
Registry data. The presence of a prospectively randomised
control arm provided a reliable baseline for interpretation.
From this we could predict either finding no difference
between the groups or a survival advantage to the trial
caused by preferential selection or closer subsequent manage-
ment. The most important selection criteria used in this
survey were considered from the outset to be only moderately
reliable tests of the clinical situation. Assessment of stage was
dependent on the accuracy and completeness of the operative
and pathological reports available for review. Post-operative
mortality was found to be the largest single factor preventing
recruitment and it also proved important to attempt to
match survivors for fitness to receive treatment.
The influence of selection on survival was potentially large
enough to obscure any real benefit or harm which might arise
from the treatment. Furthermore, using selection criteria
alone does not guarantee an equal distribution of prognostic
factors within the groups. However, comparison of the char-
acteristics of eligible cases revealed no unequivocal evidence
that the trial patients were a highly selected, good prognosis
group. Four of the five significant independent predictors of
survival within the trial (the presence of residual disease,
node, resection line involvement and overall stage) (Allum et
al., 1989a) were equally distributed. However pre-operative
weight loss, which was also significant could not be assessed
and other potentially significant factors were not well balanc-
ed. The finding that randomised patients were a significantly
younger group may well reflect poorer general fitness or
longer convalescence in more elderly patients. However, it is
possible that selection may have been influenced by clinical
bias against entering older patients. Several other screening
studies, most notably the paper by Hunter et al. (1987) have
also found an inverse relationship between increasing age and
trial entry. The excess of upper tumours and partial-proximal
resection in the non-trial group could be a result of referral
to thoracic rather than general surgeons. Retrospective data
collection could account for the shorter duration of symp-
toms reported by the non-trial cases.
Further work would be to balance the groups according to
prognostic factors, though this would again reduce the
numbers available for study (Gehan, 1980). Our experience
supports the observation made by Pocock (1976) that the
major problem with non-randomised controls is the difficulty
of ever proving that the comparison is fair. More convincing
evidence can only be obtained from well designed and con-
ducted randomised trials. The best way forward would seem
to be to utilise the improved flow of medical information to
identify suitable subjects and to facilitate the running of
prospective studies.
Cancer Registry data on the number and distribution of
potential trial subjects could prove a valuable planning aid to
future large trials. Investigators should be aware that raw
incidence data are a poor general indicator of the number
suitable for entry into even relatively 'open' protocols such as
BSCG-1. Estimates can be improved by considering the effect
of all the proposed entry criteria. The interpretation of trial
results in the context of the population being treated would
require similar care in matching suitable cases. Registry data
are subject to many different confounding factors and should
not be used as an alternative to trials when comparing
treatment differences (Green & Byar, 1984). There is however
a growing body of epidemiological evidence to suggest than
patients treated according to trial protocols or by specialist
centres do better that those managed elsewhere. These
reports come from childhood cancer centres (Stiller, 1989)
and in the rare adult tumours where major advances have
been made, such as multiple myeloma (Karjalainen & Palva,
1989) and testicular cancer (Bagshawe et al., 1985). There is
still little evidence that outcome in the common adult solid
tumours is improved by treatment at specialist centres
(Stiller, 1992). Recent work looking at the management of
breast and prostatic cancer in Finland confirms the difficulty
of attributing observed variations in survival to differences in
patterns of care (Karjalainen, 1990).
It is disappointing that in this study, 2 years of intensive
follow-up by specialist trial clinics was not translated into
improved survival over the concurrent non-trial cases. Other
large series from the West Midlands Registry have shown
that increased surgical experience can significantly reduce
post operative mortality in resectable gastric and esophageal
cancer, but long term outcome was not improved in those
who survived operation (Allum et al., 1989b; Matthews et al.,
1986). Until more effective treatments become available, early
diagnosis and improved surgical management will continue
to dominate the outcome in gastric cancer. There is a clear
need to continue to test potential adjuvant treatments for this
disease within the context of properly controlled and
executed clinical trials.
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